
    
      Patents who were treated with NA at least one year and achieved hepatitis B virus (HBV) DNA
      suppression and HBsAg level<3000 international unit (IU) /mL are enrolled in this study, they
      are assigned into two groups, in group I, patients will receive pegylated interferon plus
      entecavir/tenofovir for 48/72/96 weeks, in group II, patients will receive
      entecavir/tenofovir for 96 weeks. HBsAg loss rates at the end of treatment and sustained
      response at the end of follow up will be evaluated.
    
  